Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Journal: Breast cancer research : BCR
Published: February 11, 2020
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: May 16, 2019
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Journal: The Lancet. Oncology
Published: February 16, 2018
Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 27, 2017
Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 26, 2017
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: October 09, 2016
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Journal: The Lancet. Oncology
Published: September 01, 2016
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
Journal: OncoTargets and therapy
Published: January 22, 2016
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation.
Journal: Clinical pharmacology in drug development
Published: July 11, 2015
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 01, 2014
Some practical considerations for phase III studies with biomarker evaluations.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 05, 2014
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 29, 2014
Last Updated: 09/26/2026